JNK1 in Hematopoietically Derived Cells Contributes to Diet-Induced Inflammation and Insulin Resistance without Affecting Obesity


1Laboratory of Metabolic Stress Biology, Division of Physiology, Department of Medicine, University of Fribourg, Chemin du Musée 5, CH-1700 Fribourg, Switzerland
2Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine
3Department of Medicine, Division of Endocrinology and Metabolism
4Department of Pediatrics and Department of Medicine
5Department of Radiology, University of California, San Diego, San Diego, CA 92098, USA
6These authors contributed equally to this work.

*Correspondence: jolefsky@ucsd.edu (J.M.O.), karinoffice@ucsd.edu (M.K.)
DOI 10.1016/j.cmet.2007.09.011

SUMMARY

Obesity-induced insulin resistance is a major factor in the etiology of type 2 diabetes, and Jun kinases (JNKs) are key negative regulators of insulin sensitivity in the obese state. Activation of JNKs (mainly JNK1) in insulin target cells results in phosphorylation of insulin receptor substrates (IRSs) at serine and threonine residues that inhibit insulin signaling. JNK1 activation is also required for accumulation of visceral fat. Here we used reciprocal adoptive transfer experiments to determine whether JNK1 in myeloid cells, such as macrophages, also contributes to insulin resistance and central adiposity. Our results show that deletion of Jnk1 in the nonhematopoietic compartment protects mice from high-fat diet (HFD)-induced insulin resistance, in part through decreased adiposity. By contrast, Jnk1 removal from hematopoietic cells has no effect on adiposity but confers protection against HFD-induced insulin resistance by decreasing obesity-induced inflammation.

INTRODUCTION

Type 2 diabetes (T2D) is a common complication of obesity and a sedentary lifestyle (Hu et al., 2001) and a major threat to human health in the 21st century (Zimmet et al., 2001). Although the mechanisms by which increased adiposity contribute to T2D pathogenesis are still being unraveled, it is now well accepted that chronic low-grade obesity-induced inflammatory responses that lead to activation of protein kinases, such as IκB kinases (IKKs) and Jun kinases (JNKs), play an important role in the etiology of this most common metabolic disease (Hotamisligil, 2006; Shoelson et al., 2006; White, 2003). JNK family members are encoded by three genetic loci: the widely expressed Jnk1 and Jnk2, and Jnk3, which is mainly expressed in brain and cardiomyocytes (Karin and Gallagher, 2005; Weston and Davis, 2007). JNK1 and JNK2 isozymes have been implicated in obesity-induced glucose intolerance, and JNK1 is believed to be the major contributor (Hirosumi et al., 2002; Tuncman et al., 2006). JNK1 is chronically activated in obesity and T2D, at least in part due to lipotoxic stress (Solinas et al., 2006a; Weston and Davis, 2007). Interference with JNK1 activity by either targeted gene disruption or pharmacological inhibitors protects against obesity-induced insulin resistance (Hirosumi et al., 2002; Kaneto et al., 2004; Tuncman et al., 2006). Since JNK1 is an attractive target for prevention and treatment of T2D and obesity-induced insulin resistance (Kaneto, 2005; Karin, 2005; Manning and Davis, 2003), it is important to fully understand the mechanisms by which it participates in the pathogenesis of glucose intolerance.

Currently, studies on JNK1 action during development of insulin resistance support a common mechanism through which JNK1 activation in insulin target cells directly interferes with insulin signaling (Aguirre et al., 2000, 2002; Hirosumi et al., 2002; Kaneto et al., 2004; Solinas et al., 2006a; White, 2003). This interference is based on direct phosphorylation of insulin receptor substrates 1 and 2 (IRS1 and IRS2) at inhibitory sites that prevent recruitment to activated insulin receptor sites (Aguirre et al., 2000, 2002; Hirosumi et al., 2002; Jaeschke et al., 2004; Kaneto et al., 2004; Solinas et al., 2006a; White, 2003). Thus, JNK-mediated IRS phosphorylation disrupts downstream events such as activation of phosphatidylinositol 3-kinase (PI3K) and AKT (Aguirre et al., 2000, 2002; Lee et al., 2003; Solinas et al., 2006a; White, 2003). Inhibition of JNK1 activation in mouse models of obesity-induced insulin resistance or in cells treated with free fatty acids (FFAs) or inflammatory cytokines results in enhanced insulin-induced PI3K and AKT activation.
(Aguirre et al., 2000, 2002; Hirosumi et al., 2002; Jaeschke et al., 2004; Kaneto et al., 2004; Lee et al., 2003; Nguyen et al., 2005; Solinas et al., 2006a).

Studies in Jnk1−/− mice have shown that these animals exhibit a remarkable lean phenotype and are largely protected from diet-induced obesity (Hirosumi et al., 2002; Tuncman et al., 2006). In addition to lean and more insulin responsive, high-fat diet (HFD)-fed Jnk1−/− mice exhibit reduced expression of proinflammatory cytokines such as IL-6, TNF-α, IL-12b, MIF, and MCP1 compared to wild-type (WT) mice (Tuncman et al., 2006). These data suggest that JNK1 may also be involved in obesity-induced inflammation. Whether this function and JNK1 activation in cells other than insulin target cells contribute to the pathogenesis of obesity-induced insulin resistance and glucose intolerance is not known. We addressed this question by generating chimeric mice that lack Jnk1 either in their nonhematopoietic compartment, including all insulin target cells, or only in their hematopoietically derived cells. Our studies show that JNK1 activation in hematopoietically derived cells makes a major contribution to both HFD-induced inflammation and insulin resistance but has no impact on development of obesity per se.

RESULTS

Generation of Mice Lacking Jnk1 in Either Hematopoietic or Nonhematopoietic Compartments

To determine whether JNK1 in hematopoietically derived cells contributes to obesity-induced inflammation and glucose intolerance, we used adoptive transfer (Janowska-Wieczorek et al., 2001; Senftleben et al., 2001) to generate mice lacking Jnk1 either in either radiation-resistant (nonhematopoietic) or hematopoietically derived cells. WT and Jnk1−/− mice were lethally irradiated and reconstituted with either Jnk1−/− or WT bone marrow (Figure 1A). Flow cytometry showed that 5 weeks after bone marrow transplantation, white blood cells were efficiently reconstituted and displayed the donor Jnk1 genotype (Figure 1B). Reconstitution was essentially complete for CD11b+ cells (99%), the precursors of macrophages and dendritic cells (Figure 1B). To investigate reconstitution of resident macrophages, we PCR-genotyped different tissues 26 weeks after reconstitution. We detected chimerism in liver and adipose tissue, but not in muscle and brain (Figure 1C). Genotyping of Kupffer cells and parenchymal liver cells indicated that Kupffer cells were almost fully derived from the donor bone marrow, whereas the parenchymal cells were those of the recipient (Figure 1C).

Resistance to Diet-Induced Obesity Is Due to JNK1 Deficiency in the Nonhematopoietic Compartment

Previous studies have shown that Jnk1−/− mice are resistant to diet-induced obesity (Hirosumi et al., 2002; Tuncman et al., 2006). To determine the compartment in which JNK1 deficiency prevents obesity, WT and Jnk1−/− mice, as well as the bone marrow transplant groups (radiation chimeras), were fed normal chow or HFD for 20 weeks starting at week 6 posttransplantation (Figure 1A). As expected, no differences in body mass were observed in chow-fed mice (data not shown), and Jnk1−/− mice on HFD were largely protected from diet-induced obesity (Figure 1D). Importantly, Jnk1−/− mice reconstituted with WT bone marrow (Jnk1−/−+WT-BM chimeras) also were protected from HFD-mediated weight gain and obesity. Magnetic resonance imaging (MRI) after 16 weeks of HFD showed that Jnk1−/− mice were much leaner than WT mice and that Jnk1−/−+WT-BM chimeras were leaner than WT mice reconstituted with Jnk1−/− or WT bone marrow (WT+Jnk1−/−-BM and WT+WT-BM chimeras) (Figures 2A and 2B). Quantification of fat pad volumes by MRI showed that both visceral fat and subcutaneous fat were reduced in Jnk1−/− versus WT mice and in Jnk1−/−+WT-BM versus WT+WT-BM and WT+Jnk1−/−-BM chimeras (Figures 2A and 2B).

We conclude that resistance to diet-induced obesity in Jnk1−/− mice (Hirosumi et al., 2002) is mainly due to Jnk1 absence from a radiation-resistant cell type of a nonhematopoietic origin.

JNK1 Deficiency in the Nonhematopoietic Compartment Increases Energy Expenditure and Improves Insulin Sensitivity

Jnk1−/− mice have smaller adipocytes than WT mice (Hirosumi et al., 2002), suggesting that decreased adiposity may be due to decreased triglyceride storage rather than reduced adipocyte number. It has also been reported that Jnk1−/− mice have normal intestinal lipid uptake and a statistically insignificant tendency toward decreased food intake and increased body temperature (Hirosumi et al., 2002). To better understand the cause of the decreased adiposity, we performed energy balance studies by measuring oxygen consumption and food intake for 60 hr. During this period, we found no differences in food intake between WT and Jnk1−/− mice or between the three groups of radiation chimeras (Figures 2C and 2D). However, oxygen consumption per lean body mass was significantly higher in Jnk1−/− mice compared to their WT counterparts (Figure 2C). Furthermore, Jnk1−/−+WT-BM chimeras also exhibited a comparable increase in oxygen consumption relative to WT+WT-BM and WT+Jnk1−/−-BM chimeras (Figure 2D). These results indicate that resistance to obesity in Jnk1−/− and Jnk1−/−+WT-BM mice is due, at least in part, to increased metabolic rate in a nonhematopoietic cell type.

As expected, Jnk1−/− mice maintained for 20 weeks on HFD had improved glucose and insulin tolerance compared to similarly fed WT mice (Figures 3A and 3B). Jnk1−/−+WT-BM chimeras on HFD also exhibited improved glucose and insulin tolerance compared to similarly fed WT+WT-BM chimeras (Figures 3C and 3D). Moreover, Jnk1−/−+WT-BM mice displayed lower plasma insulin levels after intraperitoneal injection of 1 g/kg body weight of glucose compared to WT+WT-BM chimeras (see Figure S1 in the Supplemental Data available with this article online).
To better understand the basis for the improved glucose tolerance in Jnk1−/− mice and Jnk1−/−+WT-BM chimeras, we performed hyperinsulinemic-euglycemic clamp studies. Although no differences were observed in mice on chow diet (Figure S2), when maintained on HFD, Jnk1−/− mice exhibited higher glucose infusion rates than WT mice (Figure 4A). The increased insulin sensitivity in Jnk1−/− mice was due to both improved insulin-stimulated glucose disposal (Figure 4B) and suppression of hepatic glucose production (Figure 4C). Consistent with the data in Figure 3, we also observed increased insulin sensitivity in Jnk1−/−+WT-BM versus WT+WT-BM chimeras (p < 0.001) (Figure 4A), and this was due to both improved glucose disposal (p < 0.001) (Figure 4B) and enhanced suppression of hepatic glucose production (p < 0.001) (Figure 4C).

To investigate the contribution of reduced obesity to improved insulin sensitivity, we performed glucose clamp studies on a group of WT+WT-BM-L chimeras, chimeric mice on HFD that were selected post hoc on the basis of lower body weight than the average for WT+WT-BM chimeras (33.4 g versus 42.1 g body mass), because of a more moderate weight gain during HFD feeding and decreased weight recovery after the clamp surgery. The glucose infusion rate in the WT+WT-BM-L group was significantly higher than in WT+WT-BM mice and lower than in Jnk1−/−+WT-BM mice, whose average body mass was 28.3 g (Figures 4A). Likewise, WT+WT-BM-L chimeras exhibited improved glucose disposal rate and suppression of hepatic glucose production compared to WT+WT-BM mice (Figures 4B and 4C), whereas compared to the Jnk1−/−+WT-BM group, the WT+WT-BM-L chimeras exhibited decreased suppression of hepatic glucose production (p < 0.05) and a slightly lower (statistically insignificant; p = 0.098) glucose disposal rate (Figures 4B and 4C).
From these results, we conclude that Jnk1 deletion in the nonhematopoietic compartment protects against diet-induced insulin resistance at least in part because it reduces adiposity.

Absence of Jnk1 from the Hematopoietic Compartment Improves Insulin Sensitivity in Mice on High-Fat Diet
As described above, Jnk1 deletion in the hematopoietic compartment does not affect body weight, adiposity, or energy expenditure. Nonetheless, WT+Jnk1−/−-BM chimeras showed improved glucose and insulin tolerance (Figures 3E and 3F) and a faster decrease in serum insulin following intraperitoneal glucose injection (Figure S1) relative to the WT+WT-BM group. Consistent with this, hyperinsulinemic-euglycemic clamp studies demonstrated that, compared to WT+WT-BM chimeras, WT+Jnk1−/−-BM mice show improved glucose infusion rate (Figure 4A) due to enhanced insulin-stimulated glucose disposal (Figure 4B) and greater suppression of hepatic glucose production (Figure 4C).

To test whether deletion of Jnk1 in the hematopoietic compartment improves insulin signaling, we measured insulin-induced AKT phosphorylation in livers of WT+Jnk1−/−-BM and WT+WT-BM chimeras. The WT+Jnk1−/−-BM chimeras maintained on HFD showed higher levels of insulin-induced AKT activation compared to WT+WT-BM chimeras maintained on HFD, which were clearly insulin resistant relative to chow-fed counterparts (p < 0.001) (Figure 4D; Figure S3).

Absence of Jnk1 from the Hematopoietic Compartment Decreases Obesity-Induced Inflammation
Jnk1−/− mice show decreased liver expression of proinflammatory cytokine and chemokine mRNAs (IL-6, TNF-α, IL-12b, MIF, and MCP1) relative to WT mice (Tuncman et al., 2006). We assessed whether JNK1 in hematopoietic cells is directly involved in obesity-induced inflammation. Both WT+WT-BM and WT+Jnk1−/−-BM chimeras on HFD developed hepatosteatosis (Figure S4) and had similar liver triglyceride content (Figure 5A). However, real-time PCR analysis revealed decreased expression of IL-6, TNF-α, IL-12b, MIF, and MCP1, while hepatic expression of the Kupffer cell marker F4/80 in livers of WT+Jnk1−/−-BM chimeras on HFD was comparable to livers of WT+WT-BM chimeras (Figure 5B; Figure S5A). Similar results, with the exception of MCP1 mRNA, were observed when adipose tissue inflammatory mRNAs were measured (Figure 5D).

Adipose tissue from obese rodents and humans is characterized by increased numbers of resident macrophages, which largely localize around dead adipocytes, forming crown-like structures (CLSs) (Cinti et al., 2005). To enumerate CLSs, we performed MAC2 and 4',6-diamidino-2-phenylindole (DAPI) staining of adipose tissue sections from WT+WT-BM and WT+Jnk1−/−-BM chimeras on HFD. The results showed that the number of adipose tissue macrophages in WT+Jnk1−/−-BM chimeras was less than half (p < 0.001) of that in WT+WT-BM chimeras (Figure 5C), despite there being no difference in adipocyte size (Figure S6) or chemotactic activity of isolated bone marrow-derived macrophages (Figure S7). Consistent with these observations, real-time PCR analysis demonstrated lower mRNA levels of the macrophage marker F4/80 in adipose tissue from WT+Jnk1−/−-BM compared to WT+WT-BM chimeras (Figure 5D). However, there were no differences in the total number of peripheral blood...
monocytes (PBMs) (Figure S8) or the number of myeloid cells recruited to the peritoneum of WT\(^{+Jnk1^+/+}BM\) and WT\(^{++}BM\) mice injected intraperitoneally with thioglycolate (Figure S9). Therefore, the decreased number of CLSs in WT\(^{+Jnk1^+/+}BM\) mice is not due to a general defect in macrophage differentiation or recruitment.

To investigate the consequences of reduced adipose tissue inflammation on production of adipokines and FFA release, we measured serum levels of leptin, adiponectin, and FFAs. Although no significant differences in the levels of adipokines between WT\(^{+Jnk1^+/+}BM\) and WT\(^{++}BM\) chimeras were detected, we observed a tendency toward increased adiponectin (p = 0.061) and decreased leptin (p = 0.067) in WT\(^{+Jnk1^+/+}BM\) chimeras compared to the WT\(^{++}BM\) group (Figure 5F). Interestingly, WT\(^{+Jnk1^+/+}BM\) mice showed decreased circulating FFA concentrations, suggesting a role for adipose tissue macrophages in lipolysis (Figure 5G). Since lipolysis is inhibited by insulin signaling (Nishino et al., 2007), it is conceivable that the decreased levels of circulating FFAs in WT\(^{+Jnk1^+/+}BM\) chimeras are consequent to improved insulin signaling in adipose tissue due to decreased inflammation.

**JNK1 Is Required for FFA-Mediated Induction of Proinflammatory Cytokines in Macrophages**

We have previously proposed that lipotoxic stress from long-chain saturated FFAs is a major cause of JNK activation in obesity (Nguyen et al., 2005; Solinas et al., 2006a). It has also been reported that long-chain saturated FFAs,
but not polyunsaturated FFAs, induce IL-6 and TNF-α in macrophages (Shi et al., 2006). Therefore, we tested whether JNK1 directly regulates expression of proinflammatory cytokines in macrophages exposed to long-chain saturated FFAs. Incubation of peritoneal macrophages with palmitate (PA) caused robust and sustained JNK activation, whereas unsaturated FFAs caused a transient response (Figure 6A; Figure S10). Real-time PCR analysis showed that PA-mediated induction of IL-6 and TNF-α mRNAs was significantly reduced in peritoneal macrophages from Jnk1−/− mice (Figure 6B).

Since WT+Jnk1−/−-BM chimeras maintained on HFD showed improved hepatic insulin signaling compared to WT+WT-BM mice (Figures 4C and 4D), we also tested the role of JNK1 in PA-induced cytokine gene expression in primary Kupffer cells from WT and Jnk1−/− mice. As seen in peritoneal macrophages, WT Kupffer cells treated with PA showed sustained JNK activation (Figure 6C) and induction of IL-6 and TNF-α mRNAs, all of which were attenuated in Jnk1−/− Kupffer cells (Figure 6D).

To test the effect of PA-induced cytokine expression in macrophages on insulin sensitivity in insulin target cells, we incubated L6 myotubes with conditioned medium from WT peritoneal macrophages treated with PA-loaded BSA, BSA alone, or LPS as a positive control. The results show that conditioned medium harvested from PA- or LPS-treated WT macrophages inhibits insulin-dependent glucose uptake compared to medium from BSA-treated macrophages (Figure 6E; Figure S11). In contrast, conditioned media from PA- or LPS-treated Jnk1−/− macrophages did not inhibit insulin-dependent glucose uptake in L6 myotubes.

Together, these results support the hypothesis that JNK1 is an important component of the low-grade inflammatory response triggered by exposure of myeloid cells (macrophages, Kupffer cells, dendritic cells, etc.) to saturated FFAs or other molecules associated with obesity.

DISCUSSION

The currently proposed mechanism for JNK action in obesity-induced insulin resistance involves direct inhibitory phosphorylation of IRS proteins within insulin target tissues such as muscle, liver, and fat (Aguirre et al., 2000, 2002; Hirosumi et al., 2002; Solinas et al., 2006a; White, 2003). JNK-mediated IRS phosphorylation can also inhibit glucose-induced insulin production by pancreatic β cells (Solinas et al., 2006a). The studies described above suggest that JNK1 deficiency protects against diet-induced insulin resistance by at least two additional mechanisms. Absence of Jnk1 in the nonhematopoietic compartment prevents diet-induced obesity and leads to indirect improvement of insulin sensitivity through maintenance of leaner body mass. By contrast, Jnk1 deletion in the hematopoietic compartment does not affect adiposity or have a direct effect on insulin receptor signaling but still protects against HFD-mediated insulin resistance by decreasing obesity-induced inflammation. This mechanism may be particularly amenable to therapeutic intervention.

Jnk1-deficient mice maintained on HFD are leaner than WT counterparts, with redistribution of adiposity from subcutaneous to visceral fat, improved insulin sensitivity, and decreased expression of proinflammatory cytokines and chemokines (Hirosumi et al., 2002; Tuncman et al., 2006). We have used reciprocal adoptive transfer experiments to tease apart the different pathophysiological mechanisms through which JNK1 deficiency contributes...
to these parameters. As previous studies have underscored a role for myeloid cells in the development of insulin resistance by maintaining a chronic, low-grade obesity-triggered inflammatory response (Arkan et al., 2005; Lesniewski et al., 2007; Weisberg et al., 2003), we examined whether JNK1 also acts in the hematopoietic compartment from which myeloid cells are derived. To this end, lethally irradiated mice were reconstituted with bone marrow from different donors and treated with antibiotics to reduce postoperative infection and inflammation (Figure 1A). We also kept these mice on a chow diet for the first 6 weeks after reconstitution before placing them on HFD for 20 weeks. Since HFD was given to younger mice in previous studies (Hirosumi et al., 2002; Tuncman et al., 2006), we studied “unmanipulated” WT and Jnk1^{−/−} mice as a reference. We succeeded in reproducing the previously reported improved glucose and insulin tolerance and obesity resistance of Jnk1^{−/−} mice, but not the subcutaneous→visceral fat redistribution (Hirosumi et al., 2002), probably due to different experimental conditions. Nonetheless, our results allow dissociation of adipose tissue distribution from obesity-induced inflammation and insulin sensitivity.

We found that Jnk1^{−/−}+WT-BM chimeras, but not WT+Jnk1^{−/−}-BM chimeras, gained less weight than controls (Figure 1D), demonstrating that mice lacking Jnk1 in the nonhematopoietic compartment, but not in hematopoietic derivatives, exhibit reduced adiposity (Figures 2A and 2B). Thus, resistance to obesity is due to absence of Jnk1 from a nonhematopoietic cell type whose identity remains unknown but could possibly be either the adipocyte itself or a central nervous system component involved in the control of energy balance. In this regard, we observed that mice lacking Jnk1 in the nonhematopoietic compartment...
exhibited higher energy expenditure per lean body mass than control mice despite normal food intake. Since no difference in body weight was observed in the chow-fed groups, JNK1 could contribute to obesity by reducing diet-induced thermogenesis in response to HFD, a condition that leads to chronic JNK activation (Hirosumi et al., 2002).

Hyperinsulinemic-euglycemic clamp studies revealed that improved glucose tolerance in Jnk1−/−/C0 mice is due to enhanced liver and peripheral insulin sensitivity. Improved glucose and insulin tolerance were observed in both Jnk1−/−/WT-BM and WT+Jnk1−/−/BM chimeras (Figure 3), and this was also due to enhanced insulin sensitivity in liver and peripheral organs (Figure 4). Comparison of WT+WT-BM chimeras to a leaner group of control chimeras (WT+WT-BM-L) indicated that improved insulin responsiveness in Jnk1−/−/BM mice is partially due to their obesity-resistant phenotype. These results suggest that pharmacological JNK1 inhibition in non-hematopoietic tissues could protect against the negative effects of HFD by increasing metabolic rate, decreasing adiposity, and improving insulin sensitivity. However, WT+Jnk1−/−/BM chimeras showed improved insulin sensitivity without an effect on obesity. Thus, the adoptive transfer experiment allowed us to dissociate effects on obesity from effects on insulin resistance in this model.

Figure 6. Induction of TNF-α and IL-6 Gene Expression by Palmitate in Macrophages Is JNK Dependent
(A) Solid-state JNK kinase assays using protein extracts from WT peritoneal macrophages. Cells were treated over a 120 min time course with different fatty acid-loaded BSA preparations as indicated. (DHA, cis-4,7,10,13,16,19-docosahexaenoic acid.)
(B) Real-time PCR analysis of TNF-α and IL-6 mRNA from WT and Jnk1−/− peritoneal macrophages treated with 0.5% BSA or 0.5 mM palmitate (PA) loaded onto 0.5% BSA for 8 hr.
(C) Solid-state JNK kinase assay using protein extracts from Kupffer cells of WT mice. Cells were treated with 0.5% BSA or 0.5 mM PA loaded onto 0.5% BSA for 120 min.
(D) Real-time PCR analysis of TNF-α and IL-6 mRNA from WT and Jnk1−/− Kupffer cells treated as in (B).
(E) Insulin-dependent glucose uptake in L6 myotubes incubated with serum-free conditioned media from peritoneal macrophages treated with 0.5% BSA, 0.5 mM PA loaded onto 0.5% BSA, or LPS.
*p < 0.05; **p < 0.01. Error bars in (B)–(D) represent SD; error bars in (E) represent SEM.
showing that transfer of \(Jnk1^{-/-}\) hematopoietic cells into WT animals confers an insulin-sensitive phenotype with attenuated HFD-induced inflammatory markers. This observation is fully consistent with a study in which acute JNK inhibition with a specific peptide inhibitor improved liver and peripheral insulin sensitivity in obese mice without affecting body weight (Kaneto et al., 2004).

Obesity triggers a chronic low-grade inflammatory response proposed to promote insulin resistance (Hotamisligil, 2006; Shoelson et al., 2006). Obesity-induced inflammation involves increased expression of proinflammatory cytokines and chemokines and infiltration of macrophages into adipose tissue, where they surround dead adipocytes to form typical CLSs (Cinti et al., 2005). Proinflammatory cytokines in both liver and adipose tissue, as well as the number of CLSs, of HFD-fed mice were reduced upon \(Jnk1\) deletion in the hematopoietic compartment. Notably, WT+WT-BM and WT+\(Jnk1^{-/-}\)-BM animals on HFD show a comparable increase in hepatic triglycerides and steatosis (Figure 5A; Figure S4), but nevertheless, the WT+\(Jnk1^{-/-}\)-BM animals do not exhibit hepatic insulin resistance (Figure 4C). Since these mice manifest \(Jnk1\) deletion in Kupffer cells and not in hepatocytes, and since their livers show decreased expression of inflammatory markers (Figure 5B), these results suggest that increased liver triglycerides and steatosis are not sufficient to cause severe hepatic insulin resistance in our model and that the inflammatory response emanating from Kupffer cells is an important cofactor.

Correspondingly, we found that JNK1 contributes to cytokine expression in both peritoneal macrophages and Kupffer cells exposed to palmate and that factors secreted by JNK1-expressing and palmitate-treated peritoneal macrophages induce insulin resistance in cultured myotubes (Figures 6A–6E).

Effects on diet-induced insulin resistance similar to those observed in WT+\(Jnk1^{-/-}\)-BM chimeras were also seen in mice with a conditional knockout in myeloid cells of the proinflammatory kinase IKK and in bone marrow transplantation chimeras for the Cap gene (Arkan et al., 2005; Lesniewski et al., 2007). In addition, the effects of PPAR activation on insulin sensitivity are also in part attributed to anti-inflammatory action in myeloid cells (Hevener et al., 2007; Odegaard et al., 2007). At the moment, it is not clear whether JNK1, IKK, Cap, and PPAR control obesity-induced inflammation via a common pathway, but it is now evident that interference with genes involved in macrophage function can protect against HFD-induced insulin resistance by decreasing metabolic inflammation.

At present, we do not know the exact mechanism by which JNK1 inactivation in adipose tissue macrophages decreases CLS formation. However, the facts that \(Jnk1^{-/-}\) macrophages display normal chemotactic activity in response to adipocyte-conditioned medium (Figure S7) and that WT+\(Jnk1^{-/-}\)-BM chimeras have normal numbers of PBM and myeloid cells in the peritoneum after thioglycolate injection suggest that the decreased number of CLSs is not due to a defect in PBM chemotaxis. We observed that \(Jnk1^{-/-}\) macrophages display defective induction of proinflammatory cytokines in response to lipotoxic stress (Figures 6B and 6D), and WT+\(Jnk1^{-/-}\)-BM chimeras showed reduced levels of proinflammatory cytokines in adipose tissue (Figure 5E). Our data therefore suggest that expression of proinflammatory cytokines by adipose tissue macrophages (ATMs) could be required for efficient ATM recruitment into adipose tissue in response to obesity and consequent CLS formation (Figure S12). Since it has been reported that ATMs are composed of at least two different populations of macrophages expressing different markers and with different proinflammatory abilities (Lumeng et al., 2007a, 2007b), it is also plausible that JNK1 could be involved in polarization of ATMs toward the more inflammatory M1 phenotype. Both of these hypotheses imply that CLS formation is a synergistic process in which macrophage activation causes more macrophages to be recruited to adipose tissue, with the end result of increased CLS formation.

Our current understanding of the role of JNK1 in the pathogenesis of obesity-induced insulin resistance is depicted in Figure 7. In summary, JNK activation in a nonhematopoietic cell type allows fat accumulation, perhaps through decreased energy consumption, thereby contributing to insulin resistance via elevated obesity (mechanism 1). As previously described, obesity-induced chronic JNK activation interferes with insulin receptor signaling by inhibiting IRS tyrosine phosphorylation (mechanism 2). In addition, obesity-mediated JNK activation in cells of the hematopoietic compartment promotes obesity-associated inflammation.

**Figure 7. A Model of Our Current Understanding of the Role of JNK1 in Diet-Induced Insulin Resistance**

ITC, insulin target cells; MC, myeloid cells. The resistance to diet-induced obesity in \(Jnk1^{-/-}\) mice is due to nonhematopoietic ITCs (mechanism 1). JNK1 is also directly involved in the development of insulin resistance in ITCs through phosphorylation of IRS1 and IRS2 (mechanism 2) and in MCs by maintaining metabolic inflammation (mechanism 3).
and production of cytokines or other factors that induce insulin resistance in insulin target cells (mechanism 3). This would represent a two-hit process in which JNK1 in myeloid cells participates in a process causing paracrine activation of JNK1 and decreased insulin signaling in insulin target cells. As myeloid cells could be more accessible to a variety of peptide and small-molecule JNK inhibitors than other cell types, our results suggest that targeting JNK within these cells could make a significant impact in treating insulin resistance.

**EXPERIMENTAL PROCEDURES**

**Radiation Chimeras**

Mice were on the C57BL/6 background. To generate radiation chimeras, mice received a lethal dose of 10 Gy of ionizing radiation, followed by tail-vein injection of 10⁷ bone marrow cells. To quantify reconstitution efficiency, we used congenic donors and recipients that differed at the Ly5.1/Ly5.2 locus. Mice were maintained for 6 weeks on chow diet, of which 5 weeks included antibiotics (polymyxin 13 mg/l, neomycin 25 mg/l) to allow bone marrow reconstitution without postoperative infection and inflammation. Mice were placed on HFD 1 week after termination of antibiotic treatment.

**Flow Cytometry**

Reconstitution efficiency was analyzed by flow cytometric analysis of congenic Ly5.1 (CD45.2-FITC; BD Pharmingen) and Ly5.2 (CD45.1-PE; BD Pharmingen) markers on blood cells stained for CD3e-PE-Cy5 (eBiology) or CD11b-Tricolor (Caltag) to identify T cells and monocytes/macrophages, respectively. Whole blood was collected and stained with anti-CD45.2-FITC and anti-CD45.1-PE together with antibodies against T cell or macrophages markers (CD3-CyChrome or CD11b-Tricolor). Cells were washed twice and red blood cells were lysed in ACK buffer (eBiology). After two additional washes, cells were resuspended in FACS buffer and analyzed via FACS caliber BD Biosciences. Data were plotted using WinMDI2.8 software.

**PCR Genotyping**

Genomic DNA was extracted from tissues or tails by proteinase K digestion (proteinase K 0.5 mg/ml, 100 mM Tris HCl [pH 8.5], 200 mM NaCl, 5 mM EDTA, 0.2% SDS) followed by phenol chloroform extraction and ethanol precipitation. The following primers were used for Jnk1 PCR genotyping: forward 5'-CAGATACATCTGAGACTGCT-3'; reverse WT 5'-CAGATGTCCTTAAGACTCC-3'; reverse Jnk1 5'-TCTGCGATTAGCAGCTGCT-3'.

**MRI Analysis and Data Segmentation**

After 16 weeks of HFD, lean body mass and fat pad volumes were measured by MRI. Mice were imaged under 1% isoflurane anesthesia. Images were acquired using a T1-weighted in a 5 cm custom volume MRI coil using a horizontal bore 7T MR scanner measured by MRI. Mice were imaged under 1% isoflurane anesthesia after 16 weeks of HFD, lean body mass and fat pad volumes were rendered using Amira software (Template Graphic Software/Mercury Computer Systems).

**Energy Balance**

Oxygen consumption and food intake were measured via Comprehensive Lab Animal Monitoring System (Columbus Instruments). Mice (eight per group) were adapted to metabolic chambers for 2 days before collecting data every 30 min over three dark and two light cycles (12 hr each). At the end of the measurement period, metabolic chambers were inspected for food spillage. Oxygen consumption was normalized per lean body mass measured by MRI.

**Glucose and Insulin Tolerance Tests and Hyperinsulinemic-Euglycemic Clamps**

Glucose and insulin tolerance tests were performed on 6 hr-fasted mice (Supplemental Experimental Procedures). Blood was collected at 0, 30, 60, 90, and 120 min after intraperitoneal injection, and glucose concentration was measured using an Accu-Check Active glucometer (Roche). For glucose tolerance tests, mice were injected with 1 g/kg body weight of glucose. For insulin tolerance tests, mice were injected with 1 IU insulin/kg body weight. Hyperinsulinemic-euglycemic clamps were performed using 12 nM insulin/kg body weight per minute as previously described (Hvener et al., 2003) (Supplemental Experimental Procedures).

**Molecular Measurements**

Total RNA was extracted from liver, adipose tissue, or macrophage cell cultures using TRIzol reagent (Invitrogen). cDNA was prepared using a reverse transcription kit (Promega), and quantitative PCR was performed using a commercial SYBR green mix (PE Applied Biosystems) and specific primers for MCP1, IL-12b, MIF, TNF-α, and IL-6 as previously described (Tuncman et al., 2006). Cph was used as housekeeping gene control (Cph forward 5'-ATGGTCAACCCACGTTG-3'; Cph reverse 5'-TCTTGCTGTCTTTGGAATTGTC-3').

For measurement of AKT activation, livers were collected after the clamp experiments, and phospho-AKT Ser473 was quantified as previously described (Solinas et al., 2006b). JNK solid-state kinase assays were performed using GST-cJun (1–79) as a substrate were performed as previously described (Hibi et al., 1993).

**Quantification of Crown-Like Structures**

Paraffin-embedded epidymal fat pad sections were stained for MAC2 (Cedarlane Labs). Stained slides were subsequently coverslipped with DAPI-containing mounting medium (Vector Labs), Bright-field (MAC2) and fluorescence (DAPI) images were taken of three representative fields per slide in a blinded fashion using a fluorescence microscope (10× objective). Nuclei per field were quantified by counting DAPI-positive nuclei using ImageJ software. MAC2-positive CLSs per field were counted manually, and the percentage of CLSs per total number of nuclei per field was used as a measure of adipose tissue macrophage content (Lesniewski et al., 2007).

**Primary Macrophage Cell Culture and Insulin-Stimulated Glucose Uptake in Myotubes**

Peritoneal macrophages were isolated from WT or Jnk1−/− mice by peritoneal lavage 4 days after injection of 3 ml of 3% thioglycolate (Difco, BD Diagnostics) and plated in six-well plates at 10⁶ cells/well. Kupffer cells were prepared by two-step liver collagenase digestion and fractionation on a Percoll gradient as previously described (Nnalue et al., 1992). The detailed protocol for glucose uptake in L6 myotubes is provided in Supplemental Experimental Procedures.

**Statistical Analyses**

Differences between two sets of data were compared by Student’s t test, and differences over time (GTTs and ITTs) were compared by two-way ANOVA. Differences were considered significant at p < 0.05.

**Supplemental Data**

Supplemental Data include Supplemental Experimental Procedures and 12 figures and can be found with this article online at http://www.cellmetabolism.org/cgi/content/full/6/5/386/DC1/.

**ACKNOWLEDGMENTS**

G.S. and J.-L.L. generated the radiation chimeras. G.S. performed most of the experiments except for hyperinsulinemic-euglycemic clamps (performed by C.V.), CLS quantification and chemotaxis assay by...
(performed by J.G.N.), L6 myotube insulin-dependent glucose uptake (performed by G.K.B.), FACS analysis (performed by S.G.), Kupffer cell cultures (prepared by W.N.), oxygen consumption and food intake analysis (performed with the support of A.W.-B.), and MRI studies (M.S.). G.S., J.M.O., and M.K. designed the study and wrote the manuscript.

We thank A.G. Dulloo for advice on the energy balance studies and T. Trang for technical assistance with metabolic cages. G.S. was initially supported by a fellowship from the Swiss National Science Foundation. This research was supported by National Institutes of Health grants ES004151 and ES006376 to M.K. and DK033651 and DK074868 to J.M.O., University of California Discovery Grant #bio06-10567 to J.M.O., and Mentor-Based Postdoctoral Fellowships from the American Diabetes Association to J.M.O. and M.K. M.K. is an American Cancer Society Research Professor.

Received: June 12, 2007
Revised: August 21, 2007
Accepted: September 26, 2007
Published: November 6, 2007

REFERENCES


